Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
Shabir A MadhiVicky BaillieClare L CutlandMerryn VoyseyAnthonet L KoenLee FairlieSherman D PadayacheeKeertan DhedaShaun L BarnabasQasim E BhoratCarmen BrinerGaurav KwatraKhatija AhmedParvinder AleySutika BhikhaJinal N BhimanAs'ad E BhoratJeanine du PlessisAliasgar EsmailMarisa GroenewaldElizea HorneShi-Hsia HwaAylin JoseTeresa LambeMatt LaubscherMookho MalahlehaMasebole MasenyaMduduzi MasilelaShakeel McKenzieKgaogelo MolapoAndrew MoultrieSuzette OelofseFaeezah PatelSureshnee PillaySarah RheadHylton RodelLindie RossouwCarol TaoushanisHouriiyah TegallyAsha ThombrayilSamuel van EckConstantinos K WibmerNicholas M DurhamElizabeth J KellyTonya L VillafanaSarah GilbertAndrew J PollardTulio de OliveiraPenny L MooreAlex SigalAlane Izunull nullnull nullPublished in: The New England journal of medicine (2021)
A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132).